PD
JANX icon

Point72 (DIFC)’s Janux Therapeutics JANX Stock Holding History

Point72 (DIFC)’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$370K Buy
15,141
+6
+0% +$146 0.02% 331
2025
Q2 		$350K Sell
15,135
-2,528
-14% -$66.6K 0.01% 655
2025
Q1 		$477K Buy
17,663
+6,756
+62% +$255K 0.02% 653
2024
Q4 		$584K Buy
+10,907
New +$577K 0.02% 605

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Point72 (DIFC)'s JANX Position: Q3 2025 in Review

Point72 (DIFC) increased its Janux Therapeutics (JANX) stake by 0.04% in Q3 2025, buying an estimated $146 and bringing the position to 15,141 shares worth $370K. The position accounts for 0.02% of the portfolio, ranked #331.

Point72 (DIFC) first reported a position in JANX in Q4 2024 and has held it in 4 quarters since. The position peaked at $584K in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Point72 (DIFC) held 15,141 shares of Janux Therapeutics worth $370K as of Q3 2025.
  • Point72 (DIFC) bought 6 Janux Therapeutics shares in Q3 2025, an estimated $146.
  • Janux Therapeutics made up 0.02% of Point72 (DIFC)'s portfolio in Q3 2025, its #331 holding.
  • Point72 (DIFC) first reported a position in Janux Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s Janux Therapeutics position peaked at $584K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.